MetaCap

Avalo Therapeutics (AVTX) vs Oculis (OCS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalo Therapeutics (AVTX) has outperformed Oculis (OCS) over the past year, losing 62.1% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -99.9% for AVTX. Oculis is the larger company by market cap ($393.4 million vs $390.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTX-62.09%OCS-63.34%
+76%+2%-71%
Nov 21, 20251 yearNov 20, 2026
AVTX-99.89%OCS-27.66%
+251%+67%-117%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTX versus OCS key metrics
MetricAVTXOCS
Share price$6.76$7.06
Market cap$390.88M$393.35M
1-day change+0.15%-5.11%
YTD return-62.78%-64.65%
1-year return-62.09%-63.34%
5-year return-99.89%-27.29%
EPS (TTM)$-2.26$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.00K—
Revenue growth (YoY)-86.62%—
Net income (latest FY)$-78.26M—
Operating margin-123601.69%—
Net margin-132642.37%—
52-week high$24.27$34.48
52-week low$6.53$6.78
Distance from 52-week high-72.15%-79.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+414.79%+407.79%
Average volume1.80M272.83K
Shares outstanding57.82M55.72M
Employees3360
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalo Therapeutics

AVTX stock →

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Oculis

OCS stock →

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

AVTX vs OCS FAQ

Which is bigger, Avalo Therapeutics or Oculis?

Oculis (OCS) is larger, with a market capitalization of $393.35M compared with $390.88M for Avalo Therapeutics (AVTX).

Which stock has performed better over the past year, AVTX or OCS?

AVTX returned -62.09% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.

Are Avalo Therapeutics and Oculis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons